Global diabetes therapies market sees expansion in the Asia Pacific region
Diabetes is a chronic disease in which there are high levels of sugar in the blood. The World Diabetes Foundation estimates that there will be 438 million people with diabetes by the year 2030. The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018. Oral anti-diabetics were the leading category of drugs in 2010 and showed a growth rate of 6.3% from the total global sales. The total sales for insulin products increased significantly as well.
Anti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs. The bulk of product revenues come from three segments - test strips, insulin and anti-diabetic drugs - which will remain the largest sources of product revenues over the next ten years. The most significant growth, however, will come from the nascent segment of continuous blood glucose monitors, which provide significantly added clinical benefit at only a modestly higher cost compared to standard blood glucose meters.
the key players in the global market for diabetes therapies include Eli Lilly, Novo Nordisk and Merck. Anti-diabetic products include insulin, insulin delivery devices, test strips, blood glucose meters and anti-diabetic drugs. The majority of product revenues emanate from just three segments - insulin, test strips and anti-diabetic drugs. It is expected that these three segments will remain the most important sources of product revenues over the next decade.
Diabetes is a chronic disease in which there are high levels of sugar in the blood. The World Diabetes Foundation estimates that there will be 438 million people with diabetes by the year 2030. The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018. Oral anti-diabetics were the leading category of drugs in 2010 and showed a growth rate of 6.3% from the total global sales. The total sales for insulin products increased significantly as well.
Anti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs. The bulk of product revenues come from three segments - test strips, insulin and anti-diabetic drugs - which will remain the largest sources of product revenues over the next ten years. The most significant growth, however, will come from the nascent segment of continuous blood glucose monitors, which provide significantly added clinical benefit at only a modestly higher cost compared to standard blood glucose meters.
the key players in the global market for diabetes therapies include Eli Lilly, Novo Nordisk and Merck. Anti-diabetic products include insulin, insulin delivery devices, test strips, blood glucose meters and anti-diabetic drugs. The majority of product revenues emanate from just three segments - insulin, test strips and anti-diabetic drugs. It is expected that these three segments will remain the most important sources of product revenues over the next decade.
No comments:
Post a Comment